JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Kodu・Aktsiate loetelu・Editas Medicine Inc

Editas Medicine Inc

Suletud

SektorTervishoid

2.18 -0.91

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.1

Max

2.21

Põhinäitajad
By Trading Economics
Sissetulek	-31M -76M
Müük	-26M 4.7M
Kasumimarginaal	-1,633.491
Töötajad	246
EBITDA	-28M -72M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+32.27% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	13. aug 2025

Turustatistika
By TradingEconomics
Turukapital	85M 214M
Eelmine avamishind	3.09
Eelmine sulgemishind	2.18

Uudiste sentiment

By Acuity

50%

162 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.33 / 1.54 Toetus ja vastupanu

Editas Medicine Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. aug 2025, 17:49 UTC

Suurimad hinnamuutused turgudel

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11. aug 2025, 17:18 UTC

Suurimad hinnamuutused turgudel

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11. aug 2025, 16:25 UTC

Tulu

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11. aug 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11. aug 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11. aug 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11. aug 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11. aug 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11. aug 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11. aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. aug 2025, 20:37 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11. aug 2025, 20:37 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Bakkt Holdings 2Q Rev $577.9M >BKKT

11. aug 2025, 20:37 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement 2Q Rev $25.8M >EXOD

11. aug 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11. aug 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11. aug 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11. aug 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11. aug 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11. aug 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11. aug 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11. aug 2025, 16:42 UTC

Omandamised, ülevõtmised, äriostud

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11. aug 2025, 16:27 UTC

Omandamised, ülevõtmised, äriostud

BBVA Says Sabadell Offer Remains in Effect

11. aug 2025, 16:26 UTC

Omandamised, ülevõtmised, äriostud

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11. aug 2025, 16:25 UTC

Omandamised, ülevõtmised, äriostud

Banco de Sabadell Announced TSB Sale on July 1

11. aug 2025, 16:25 UTC

Omandamised, ülevõtmised, äriostud

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Võrdlus sarnastega

Hinnamuutus

Editas Medicine Inc Prognoos

Hinnasiht

By TipRanks

32.27% tõus

12 kuu keskmine prognoos

Keskmine 2.91 USD 32.27%

Kõrge 4 USD

Madal 1 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Editas Medicine Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Editas Medicine Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.33 / 1.54Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Sentiment

By Acuity

162 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.